Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
This is a pilot, proof of concept, placebo-controlled, parallel study. Participants will be recruited from NYU Langone Medical Center's Ear, Nose \& Throat (ENT) Department and will receive either high-dose intranasal oxytocin or a nasal spray containing Pcca Mucolox and distilled water, serving as the placebo. Long term treatment with high-dose oxytocin (45 IU four times daily) may reduce the frequency and severity of tinnitus, the burden tinnitus symptoms cause patients, and improve their quality of life.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with continuous perception of subjective tinnitus for ≥ 6 months duration.
Subjects must have had a normal otolaryngologic evaluation within the past year with no evidence of otitis media or externa, a Tinnitus Handicap Inventory (THI) of \> 16.
Subjects must have tinnitus loudness rating of \>4/10.
You may not be if
Subjects who are being treated for tinnitus \< 6 months due to the acute nature of their condition
Subjects who have a slight handicap according to the Tinnitus Handicap Inventory Severity Scale.
Those with tinnitus of a muscular or vascular etiology
Subjects with conductive hearing loss, history of migraine, or prior use of oxytocin nasal spray.
Women of childbearing age will not be approached for participation due to the risk of oxytocin-induced uterine contractions.
Subjects who suffer from migraines.
Subjects who have history of pulmonary edema, Congestive Heart Failure, and severe renal disease.